P-89 The correlation between adverse events and survival benefits of donafenib in the first-line treatment of advanced hepatocellular carcinoma
F. Bi,S. Qin,J. Xu,C. Du,Q. Fan,L. Zhang,M. Tao,D. Jiang,S. Wang,Y. Chen,J. Sheng,X. Zhuang,J. Wu,L. Liu
DOI: https://doi.org/10.1016/j.annonc.2021.05.144
IF: 51.769
2021-01-01
Annals of Oncology
Abstract:Donafenib is a new generation small molecule multi-kinase inhibitor. An open-label, randomized, parallel-controlled phase II/III clinical trial (ZGDH3) has demonstrated that donafenib significantly prolongs the overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) compared to sorafenib, and has better safety and tolerability. Certain adverse effects of sorafenib have been reported to be predictive of efficacy. Therefore, this article aimed to explore and analyse the correlation between donafenib-related adverse events (AE) and efficacy. Patients with unresectable/metastatic HCC, Child-Pugh score ≤7, and no prior systemic therapy were enrolled in the ZGDH3 study and randomized 1:1 to receive oral donafenib (0.2 g) or sorafenib (0.4 g) bid. AEs were evaluated according to the NCI CTCAE v4.0. OS and time to progression (TTP) were compared in groups based on the presence/absence of specified treatment-related AEs (TRAE). The statistical analysis population for this report included all patients who had taken at least one dose of donafenib (safety set, SS). A total of 333 patients were included in the donafenib SS set. The TRAEs involved in this analysis included hand-foot skin reactions (HFSR), diarrhea, thrombocytopenia, hypertension, elevated aspartate aminotransferase (AST), alopecia, rash, elevated blood bilirubin, proteinuria, elevated alanine aminotransferase (ALT), and fatigue. Univariate analysis showed that the mOS of patients who experienced HFSR, diarrhea, thrombocytopenia, hypertension, alopecia, rash, and proteinuria were significantly longer than that of those without these side effects (HFSR: 17.6 vs 7.9 months, HR 0.498, 95% CI 0.384–0.648, P <0.0001; Diarrhea: 16.2 vs 10.3 months, HR 0.663, 95% CI 0.497–0.884, P =0.0049; Thrombocytopenia: 15.8 vs 10.4 months, HR 0.582, 95% CI 0.433–0.783, P =0.0003; Hypertension: 15.7 vs 9.8 months, HR 0.596, 95% CI 0.454–0.782, P =0.0002; Alopecia: 18.1 vs 10.4 months, HR 0.629, 95% CI 0.453–0.875, P =0.0054; Rash: 15.3 vs 10.5 months, HR 0.644, 95% CI 0.459–0.901, P =0.0097; Proteinuria: 13.1 vs 10.7 months, HR 0.761, 95% CI 0.583–0.994, P =0.0438), while the mOS of patients with fatigue was significantly shorter than those without it (8.3 vs 12.6 months, HR 1.607, 95% CI 1.115–2.315, P =0.0103). There were also statistically differences in mTTP between patients with HFSR, diarrhea, thrombocytopenia, hypertension, alopecia, and rash and those without them (P < 0.05). The occurrence of HFSR, diarrhea, thrombocytopenia, hypertension, alopecia, rash, and proteinuria were correlated with longer survival benefits, whereas fatigue was associated with a shorter OS. These adverse events could serve as predictors of the efficacy of donafenib in the treatment of advanced HCC.